📣 VC round data is live. Check it out!
- Public Comps
- Standard BioTools
Standard BioTools Valuation Multiples
Discover revenue and EBITDA valuation multiples for Standard BioTools and similar public comparables like Delcath Systems, Myriad Genetics, IVF hartmann, ClearPoint Neuro and more.
Standard BioTools Overview
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Founded
1999
HQ

Employees
818
Website
Financials (LTM)
Market Cap
$392M
Valuation Multiples
Start free trialStandard BioTools Financials
Standard BioTools reported last 12-month revenue of $84M and negative EBITDA of ($45M).
In the same LTM period, Standard BioTools generated $43M in gross profit, ($45M) in EBITDA losses, and had net loss of ($52M).
Revenue (LTM)
Standard BioTools P&L
In the most recent fiscal year, Standard BioTools reported revenue of $85M and EBITDA of ($62M).
Standard BioTools is unprofitable as of last fiscal year, with gross margin of 50%, EBITDA margin of (73%), and net margin of (88%).
Financial data powered by Morningstar, Inc.
Standard BioTools Stock Performance
Standard BioTools has current market cap of $392M.
Market Cap Evolution
Standard BioTools' stock price is $1.00.
Standard BioTools share price increased by 8.5% in the last 30 days, and decreased by 0.5% in the last year.
Standard BioTools has an EPS (earnings per share) of $-0.19.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $392M | 1.5% | 8.5% | -11.1% | -0.5% | $-0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStandard BioTools Valuation Multiples
Standard BioTools trades at (0.4x) EV/Revenue multiple, and 0.7x EV/EBITDA.
EV / Revenue (LTM)
Standard BioTools Financial Valuation Multiples
As of May 13, 2026, Standard BioTools has market cap of $392M.
Standard BioTools has a P/E ratio of (7.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Standard BioTools Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Standard BioTools Margins & Growth Rates
Standard BioTools decreased revenue by 3% and EBITDA by 74% in the last fiscal year.
In the most recent fiscal year, Standard BioTools reported gross margin of 50%, EBITDA margin of (73%), and net margin of (88%).
Standard BioTools Margins
Standard BioTools Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Standard BioTools Operational KPIs
Standard BioTools' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Standard BioTools' Rule of 40 is (23%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Standard BioTools' Rule of X is (28%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Standard BioTools Competitors
Standard BioTools competitors include Delcath Systems, Myriad Genetics, IVF hartmann, ClearPoint Neuro, TaiDoc Technology, Coltene, Revenio Group, Medios, Advanced Technology Company and Universal Vision.
Most Standard BioTools public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.6x | 3.3x | 12.1x | 17.6x | |||
| 0.6x | 0.6x | 12.1x | 12.2x | |||
| 1.2x | — | 7.7x | — | |||
| 10.6x | 9.1x | (25.7x) | (25.1x) | |||
| 1.8x | — | 4.0x | — | |||
| 1.3x | 1.3x | 11.1x | 10.8x | |||
| 3.1x | 2.7x | 10.9x | 10.6x | |||
| 0.3x | 0.2x | 7.7x | 5.5x | |||
This data is available for Pro users. Sign up to see all Standard BioTools competitors and their valuation data. Start Free Trial | ||||||
Standard BioTools M&A Activity
Standard BioTools has acquired 2 companies to date.
Last acquisition by Standard BioTools was on October 4th 2023. Standard BioTools acquired SomaLogic for $1B (EV/Revenue multiple of ).
Latest Acquisitions by Standard BioTools
| Description | SomaLogic is a Boulder-headquartered proteomics company offering SOMAscan assays for biomarker discovery. Its SOMAmer reagents detect over 7,000 proteins from 100 microliters of sample, applied in oncology, cardiovascular, neurology, and metabolic research. Founded in 1999, the company partners with Pfizer and Novartis and processed samples for over 1 million subjects in studies. | DVS Sciences is a California-based developer of mass cytometry technology for biomedical research and clinical diagnostics. The company manufactures the CyTOF system, which enables high-parameter single-cell analysis by combining time-of-flight mass spectrometry with metal-tagged antibodies from its Maxpar reagent line. Installed in research institutions across North America, Europe, and Asia, CyTOF instruments profile up to 50 markers per cell, advancing applications in immunology, oncology, and immunotherapy. |
| HQ Country | ||
| HQ City | Boulder, CO | San Francisco, CA |
| Deal Date | 4 Oct 2023 | 29 Jan 2014 |
| Valuation | $1B | $208M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Standard BioTools acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Standard BioTools
| When was Standard BioTools founded? | Standard BioTools was founded in 1999. |
| Where is Standard BioTools headquartered? | Standard BioTools is headquartered in United States. |
| How many employees does Standard BioTools have? | As of today, Standard BioTools has over 818 employees. |
| Who is the CEO of Standard BioTools? | Standard BioTools' CEO is Michael Egholm. |
| Is Standard BioTools publicly listed? | Yes, Standard BioTools is a public company listed on Nasdaq. |
| What is the stock symbol of Standard BioTools? | Standard BioTools trades under LAB ticker. |
| When did Standard BioTools go public? | Standard BioTools went public in 2011. |
| Who are competitors of Standard BioTools? | Standard BioTools main competitors include Delcath Systems, Myriad Genetics, IVF hartmann, ClearPoint Neuro, TaiDoc Technology, Coltene, Revenio Group, Medios, Advanced Technology Company, Universal Vision. |
| What is the current market cap of Standard BioTools? | Standard BioTools' current market cap is $392M. |
| What is the current revenue of Standard BioTools? | Standard BioTools' last 12 months revenue is $84M. |
| What is the current revenue growth of Standard BioTools? | Standard BioTools revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of Standard BioTools? | Current revenue multiple of Standard BioTools is (0.4x). |
| Is Standard BioTools profitable? | No, Standard BioTools is not profitable. |
| What is the current EBITDA of Standard BioTools? | Standard BioTools has negative EBITDA and is not profitable. |
| What is Standard BioTools' EBITDA margin? | Standard BioTools' last 12 months EBITDA margin is (54%). |
| What is the current EV/EBITDA multiple of Standard BioTools? | Current EBITDA multiple of Standard BioTools is 0.7x. |
| How many companies Standard BioTools has acquired to date? | As of May 2026, Standard BioTools has acquired 2 companies. |
| What was the largest acquisition by Standard BioTools? | $1B acquisition of SomaLogic on 4th October 2023 was the largest M&A Standard BioTools has done to date. |
| What companies Standard BioTools acquired? | Standard BioTools acquired SomaLogic and DVS Sciences. |
| In how many companies Standard BioTools has invested to date? | Standard BioTools hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Standard BioTools
Lists including Standard BioTools
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
